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1. Introduction 
Designing antibiotic dosing regimens is often not optimal and the dose-response 
relationship for most antibiotics is not well-known1. Both Pharmacokinetics (PK) and 
Pharmacodynamics (PD) are characteristics of antimicrobial agents that should be 
considered in the development of effective antibiotic therapy. By linking the concentration 
time profile at the site of action to the drug effect (PK/PD), the effect of varying dosage 
regimens against pathogens could be simulated enabling the identification of effective 
dosage strategies. It is known that inadequate antibiotic dosing could not only lead to a 
therapeutic failure, but also to the development of bacterial resistance. Importantly, the 
evolution of resistance in pathogenic bacteria combined with the decreasing interest from 
the pharmaceutical industry in developing new antibiotics has created a major public health 
problem3. Therefore, the activities to maintain the effects of existing antibiotics and prolong 
their useful life span have a high priority.  
PK/PD analysis proved to be a useful tool for investigating effective therapies that minimize 
the emergence of antibiotic tolerance. Although the European Medicine Agency and FDA 
clearly recommends PK/PD assessment for new compounds, there are no standardized 
procedures for such analyses for antibiotics3. For characterizing the PD of an antibiotic, 
bacterial growth and death under antibiotic exposure have to be investigated. Since these are 
difficult to measure in human tissues, animal and in vitro models have been developed.  
Although animal models provide similar growth conditions for bacteria and imitate the 
characteristics of human infection, they exhibit different PK and drug disposition profiles 
compared to humans4. In contrast, in vitro models have the advantage of simulating human 
PK and bacterial resistance analysis. Therefore, they are considered adequate for the 
investigation of antimicrobial activity4. 
Frequently, the pharmacodynmic relationship is reduced to a single parameter, the 
Minimum inhibitory concentration (MIC), even though antibiotics with the same MIC can 
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have different PD functions1. Differences in the kill profiles exhibited by antibiotics is 
hypothesized to be influenced by disparities of their PD characteristics that- if not taken into 
account during the design of treatment regimens- may lead to therapeutic failure and 
development of resistance.  
In this study, five antibiotics of five different classes were considered for PK/PD analysis. 
The antibiotics were Ciprofloxacin (a fluorquinolone that acts by inhibiting bacterial DNA 
gyrase enzyme), Ampicillin (a beta-lactam antibiotic acts by inhibiting bacterial cell wall 
synthesis), and finally Rifampin, Streptomycin, and Tetracycline (protein synthesis 
inhibitors). The antibiotics were further classified according to their pharmacodyamic 
properties into concentration dependent antibiotics (Ciprofloxacin, Rifampin and 
Streptomycin), and time dependent antibiotics (Ampicillin and Tetracycline).   
PK/PD simulations using STELLA® (Version 9.1, isee system inc, NH, USA) were used to 
investigate the effect of various PD parameters on the achievement of the therapeutic 
outcome and in designing effective dosing regimen that help overcome the development of 
resistance to the antibiotic. 
2. Pharmacokinetic analysis 
The PK of the antibiotics was assumed to follow one compartment disposition 
characteristics with a first order elimination rate constant. The drug was given in a dose that 
gave an initial plasma concentration equivalent to 5 times the MIC and the plasma 
concentration was allowed to decrease mono-exponentially to a minimum of 0.5 times the 
MIC over 8 hours according to the following equation 
 Ct=C0 exp{-kt}  (1) 
Where Ct is the plasma concentration at time t, C0 is the initial plasma concentration and k is 
the first-order elimination rate constant. 
Doses were administered as multiple IV boluses with a time interval of 8 hours. The system 
was assumed to be at a steady state. The volume of distribution was assumed to be fixed 
(equals 1); since the data were obtained from an in vitro experiment. Clearance (k*v) was 
then assumed to be equivalent to the value of the elimination rate constant k. For this 
analysis, Ciprofloxacin, Ampicillin, Rifampin, Streptomycin and Tetracycline were the 
considered antibiotics. 
3. Pharmacodynamic analysis 
3.1 Effect of exposure to antibiotics on the bacterial net growth rate 
The net growth rate under certain antibiotic pressure could be described by the following 
equation:- 
 ( ) max ( )a a     (2) 
Where is the net growth rate at antibiotic concentration a, is the growth rate of the bacteria 
in absence of antibiotic, and is the death rate of the bacterial population exposed to an 
antibiotic concentration a. Therefore, the net growth rate of the bacterial population under 
antibiotic treatment could be described by the following model:- 
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Whereis the minimum net growth rate of the bacteria at high antibiotic concentration, a is 
the antibiotic concentration, zMIC is the pharmacodynamic MIC (concentration of the 
antibiotic at which the net bacterial growth rate was calculated to be zero), and K is the Hill 
coefficient which is a measure of the steepness of the sigmoidal relationship between 
antibiotic concentration and the net growth rate. 
The model was constructed to evaluate the effect of the antibiotics against a single micro-
organism (E. coli); and therefore, the maximum growth rate is assumed to be constant. 
The minimum growth rate, zMIC as well as the Hill coefficient will, however, change due to 
different antibiotic treatments. Bacterial net growth rate against the antibiotic concentration 
was analyzed for the aforementioned antibiotics. 
4. PK/PD analyses 
The bacterial population was modeled during the mono-exponential growth phase. The 
change in bacterial density was modeled according to the following equation:- 
dx/dt = growth rate – kill rate due to antibiotic 
Where x is the bacterial density measures in colony forming units per mL (CFU/mL) 
Time plots of the logarithm to the base 10 of the bacterial density were generated and the 
effect of the PD parameters (MIC, K, minimum growth rate, and maximum growth rate) on 
the achievement of the target treatment outcome was investigated through a sensitivity 
analysis in STELLA®. The target treatment outcome was defined as three log10 decrease in 
the bacterial density over a 24 hour course of the treatment. 
4.1 Design of antibiotics treatment strategies 
Antibiotics are generally classified to concentration dependent and time dependent agents. 
In the current analysis, treatment strategies were constructed and tested under different 
scenarios. Results from the simulation were used to conclude on the most appropriate 
treatment option for different classes of antibiotics.  
Increasing the MIC by two fold and four folds supported the simulation of bacterial 
resistance against the antibiotic treatments. The outcome target of the treatment is to 
achieve three log10 decrease in the bacterial density over a 24 hours course of treatment 
through the given dosage regimen. Towards that target, two treatment strategies were 
used. The first was to increase the area under the antibiotic concentration time curve 
above the minimum inhibitory concentration (AUC>MIC) through increasing the 
administered dose, while the second was to increase the percentage of time during which 
the drug concentration is above the MIC relative to the dosing interval (% t>MIC) through 
decreasing the dosing interval with smaller maintenance doses. Both scenarios were 
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applied to each of the investigated antibiotics and the outcomes of the treatment regimens 
were compared. 
5. Results 
5.1 The pharmacokinetic model  
The disposition of the antibiotics was shown to follow a one compartment model with a first 
order elimination rate. The achievement of the steady state was assumed form the beginning 
of therapy. (Figure 1a and 1b) 
The antibiotics were given as multiple intravenous boluses every 8 hours over a course of 24 
hours. 
amt Ampicillin
Amp dosing rate Amp elim rate
v ol amp
cl amp
conc amp
log conc Amp
 
Fig. 1a. STELLA model simulating the one compartment PK model with first order 
elimination rate constant for Ampicillin  
 
Fig. 1b. Simulation of the Ampicillin steady state concentration time profile form the PK 
model.  
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5.2 Pharmacodynamic analysis 
5.2.1 Effect of antibiotic concentration on the bacterial net growth rate 
Changing antibiotic concentration is assumed to be affecting the net growth rate of the 
bacteria cultured in the in vitro system. The infection was therefore assumed to occur in the 
central compartment. The pharmacodynamic parameter estimates for the five considered 
antibiotics are displayed in Table 1. STELLA model (Figure 2) was created to determine the 
effect of changing drug concentration on the net bacterial growth rate according the 
pharmacodynamic function expressed in equation 3. 
 
PD parameter/ 
drug 
Max. growth 
rate (h-1) 
Min. growth 
rate (h-1) 
K zMIC (µg/mL) 
Ciprofloxacin 0.75 -6.5 1.1 0.017 
Ampicillin 0.75 -4.0 0.75 3.4 
Rifampin 0.75 -4.3 2.5 12.0 
Streptomycin 0.75 -8.8 1.9 18.5 
Tetracycline 0.75 -8.1 0.61 0.67 
Table 1. Pharmacodynamic parameter estimates1  
 
Fig. 2. Sketch of the STELLA model used to assess the pharmacodynamic effect of the 
antibiotic Ampicillin. 
Bacterial net growth rate against the antibiotic concentration displayed a nonlinear 
inhibitory PD function with increasing antibiotic concentration. It is assumed that the four 
PD parameters (MIC, K, minimum growth rate, and maximum growth rate) contribute to 
the shape of the PD curve. 
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It is noticed that concentration dependent antibiotics (Ciprofloxacin, Rifampin, and 
Streptomycin) showed a sharper decrease in the net growth rate in relation to antibiotic 
concentration (greater K value), while time dependent antibiotics (Ampicillin and 
Tetracycline) showed slower decline with respect to increase in concentration (lower K 
values) (Figure 3). Additionally, Figure 4 shows that three antibiotics with the same MIC 
values and minimum growth rate against a specific microorganism can have different 
microbiological activity depending on the value of the Hill coefficient K. 
 
Fig. 3. Effect of antibiotic concentration on bacterial net growth rate  
 
Fig. 4. Pharmacodynamic sensitivity analysis shows the effect of three antibiotics with the 
same MIC and minimum growth rate on the bacterial net growth rate due to different 
values of Hill coefficient (K).  
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5.3 PK/PD analysis 
Change in the bacterial density over time was modeled using STELLA as in figures 5a and 
b. the model assumes that bacterial growth over time follows an exponential pattern. 
 
Fig. 5a. STELLA model constructed to investigate the change in bacterial density over time. 
 
Fig. 5b. Bacterial growth curve from the PD model.  
The drug effect was added to the previous model through the inclusion of a first order kill rate. 
This resulted in a decline in the log10 bacterial density over time. The decline was found to be 
governed by the magnitude of the PD model parameters. The effect of the Hill coefficient, the 
minimum growth rate, and the maximum growth rate was investigated for both concentration 
dependent and time dependent agents. The values of the PD parameters that were used in the 
sensitivity analysis are reported in Table 2. The results from the sensitivity analysis are shown 
in Figures 6, 7 and 8. It is noticed that as K increases, there is a sharper decline in the bacterial 
density due to a faster rate of killing. In addition, on the single dose level, ciprofloxacin 
showed greater rate of killing compared to ampicillin (Figure 6). 
Similarly, minimum growth rate achieved under high antibiotic concentration was related to 
the treatment outcome. Increased minimum growth rate under certain high antibiotic 
pressure, led to a decreased antibiotic efficacy. This could be attributed to development of 
resistance. It is also noticed that the effect was greater for concentration dependent 
antibiotics than the for time dependent agents (Figure 7).  
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PD parameter Hill coefficient (K) 
Minimum growth 
rate (h-1) 
Maximum growth 
rate (h-1) 
Scenario 1 0.5 -3 0.75 
Scenario 2 1 -6 1.2 
Scenario 3 3 -9 2 
Table 2. Pharmacodynamic parameters incorporated in the sensitivity analysis 
 
Fig. 6. Effect of the Hill coefficient (K) on the treatment outcomes for both Ciprofloxacin and 
Ampicillin.  
 
 
Fig. 7. Effect of variation of minimum growth rate achieved under high antibiotic 
concentration on the treatment outcomes for the investigated antibiotics.  
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In addition to the previously mentioned PD parameters, maximum growth rate of the 
bacteria achieved in the absence of antibiotic was an influential parameter. Change in that 
parameter could be considered when the effect of the antibiotic on different bacterial strains 
is a point of interest. Moreover, it could be important for a single microbial strain. For 
instance, it is known that the growth rate of the bacterial biofilm is reduced compared to the 
planktonic cultures due to the development of a matrix of extracellular polymeric substance 
that is referred to as a slime2. This will result in reduced penetration of the antibiotics as well 
as nutrients. Figure 8 augments that by showing that the increase in the maximum growth 
rate led to a more susceptible micro-organism and a faster kill by the antibiotic.  
 
Fig. 8. Effect of variation of maximum growth rate of the microorganism on the treatment 
outcome with Ciprofloxacin, Tetracycline and Ampicillin.  
6. Development of microbial resistance 
Development of microbial resistance is a major challenge that faces antibiotic treatments and 
causes reduction in the treatment efficacy. In order to simulate cases of bacterial resistance, 
MIC values were allowed to vary two and four fold from the original MIC through 
conducting a zMIC sensitivity analysis (Table 3). The pharmacokinetic profiles of the five 
antibiotics were simulated using the previously mentioned one compartment disposition 
model. It is noticed that as the MIC increases, the level of resistance of the microorganism 
increases, thus an expected reduction in the rate of kill will occur. Under such 
circumstances, the antibiotic may no longer be effective in eradicating the microorganism as 
shown in Figure 9 
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MIC (µg/mL) 
/antibiotic 
Scenario 1 Scenario 2 Scenario 3 
Ciprofloxacin 0.017 0.034 0.068 
Ampicillin 3.4 6.8 13.6 
Rifampin 12 24 48 
Streptomycin 18.5 37 74 
Tetracycline 0.67 1.34 2.68 
Table 3. MIC values incorporated in the sensitivity analysis for simulating the development 
of resistance. 
 
Fig. 9. Effect of the development of resistance (simulated through increasing zMIC) on the 
antimicrobial outcome for the different antibiotics.  
7. Design of treatment strategies  
Each of the five antibiotics was allowed to follow two treatment scenarios to overcome the 
emergence of the resistant microbe (Figure 10) and the treatment outcome was then 
evaluated. Treatment modalities included two protocols: the first implemented a method to 
increase the AUC/MIC by increasing the doses of the antibiotic. The second allowed the 
percentage of time that the drug concentration stays above the MIC to increase by 
decreasing the dosing interval while giving small maintenance doses of the antibiotic. 
Shown in Figure 10 is a representation of the concentration profiles expected from the 
treatment scenarios and in Figures 11a, b, and c are the simulated treatment outcomes 
expected from each protocol for three of the antibiotics. 
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Fig. 10. Simulation of the concentration time profile for the treatment scenarios proposed to 
overcome resistance. 1. Represents original treatment protocol. 2. Represents increasing 
AUC>MIC scenario and 3. Represents the case of increased % t>MIC. 
 
Fig. 11a. Simulation of the target outcome for the two treatment scenarios used against the 
Rifampin resistance. Upper left: increasing the dose of Rifampin 1.5 folds over 8 hours 
interval. Upper right: decreasing the dosing interval to 4 hours while maintaining the 
original dose. Down: decreasing the dosing interval to 2 hours while maintaining the 
original dose. 
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Fig. 11b. Simulation of the treatment outcomes obtained after implementation of the two 
treatment scenarios with Ciprofloxacin. Left side curve represents increasing the dose by 
four times over 8 hours dosing interval. Right side curve represents decreasing the dosing 
interval by 4 hours while maintaining the original dose. 
Rifampin is known to be a concentration-dependent antibiotic. Increasing the exposure to the 
drug above the MIC (by 1.5 fold increase in the dose) improved the treatment outcome, yet 
increasing the percentage of time relative to the dosing interval (tau) that the drug 
concentration was above the MIC- by decreasing tau from 8 hours to 4 and 2 hours 
simultaneously- did not achieve the target outcome even when the dosing interval decreased 
to 2 hours. Ciprofloxacin- a fluoroquinolone known to be a concentration dependent 
antibiotic- displayed similar results to Rifampin upon increasing exposure above MIC (four 
fold increase in the dose) compared to t>MIC (reducing the dosing interval to 2 hours).  
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Fig. 11c. Simulation of the treatment outcomes achieved after increasing Tetracycline dose 
(four folds over 8 hours dosing interval, left side curve), or decreasing the dosing interval (2 
hours, while maintaining original dose, right side curve). 
On the other hand, the efficacy of Tetracycline is known to be time dependent. Therefore, 
increasing the percent of time the drug stays above MIC relative to the dosing interval 
seems to be more relevant than increasing the exposure above the MIC. Surprisingly, the 
two scenarios have achieved nearly the same treatment outcome for microbial resistance 
against Tetracycline. Both treatment scenarios succeeded to achieve the target outcome of 
three log10 reduction in bacterial density by the end of the antibiotic treatment.  
8. Discussion 
This study addressed the complex relationship between the exposure to antibiotics and the 
growth and death rates of bacteria. PK/PD simulations using STELLA showed that 
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although MIC is an important PD parameter, it is not the only parameter that governs the 
interaction of the antibiotic and the bacteria. Other PD parameters should additionally be 
taken into consideration when designing antibiotic dosage regimens. For instance, Figure 4 
showed that three antibiotics with the same MIC (the concentration corresponding to a net 
growth of zero) could show different microbiological activity depending on the magnitude 
of the Hill coefficient (K). Other PD parameters to be considered are the minimum growth 
rate and the maximum growth rate, which can capture effects that cannot be accounted for 
by solely considering the MIC and can importantly affect the therapeutic outcomes.  
Pharmacodynamic simulations of the antibiotics concentration against net bacterial growth 
showed that the shape of the sigmoidal functions differs among antibiotics from different 
classes with some of them showing greater sensitivity to changing concentrations 
(Ciprofloxacin and Streptomycin) than others (Tetracycline and Ampicillin). The shape of 
the pharmacodynamic function is determined by the values of PD parameters displayed in 
Table 2. 
Additionally, using a STELLA model for the change in bacterial density over time, it was 
found that the parameters that govern the PD function have a profound effect on the 
microbiological activity. The Hill coefficient influences the sensitivity of the bacteria to the 
change in the antibiotic concentration as was shown in Figure 4. Assuming a PK model in 
which the drug reaches steady state form the beginning of the treatment, a concentration 
that is above the MIC most of the time, and all other parameters are equal, the simulation 
predicts that antibiotics with a high Hill coefficient are more effective than those with a low 
value of the coefficient.  
Considering the minimum bacterial net growth rate at high antibiotic concentrations, the 
simulation predicts that antibiotics that induced lower values of minimum bacterial net 
growth rate are more effective than those with higher values. Increase in the minimum 
bacterial net growth rate could be atrributed to the development of resistance or to the 
utilization of ineffective therapy against a specific bacterial strain. 
Maximum growth rate in the absence of antibiotic is another important parameter to 
consider in the design of antibiotic treatment. That PD parameter is subject to change when 
treating different micro-organisms or if the nature of infection by the same microbe has been 
changed. Regarding the later condition, biofilm infection could be considered as a change in 
the nature of the infection by the same micro-organism5. It is well-known that biofilm is a 
type of persistent infections that is developed in chronic disease statuses and is 
characterized by a slower rate of growth compared to acute infections2. This phenomenon is 
also observed in the in vitro systems- where the planktonic cultured bacteria exhibit a faster 
rate of growth compared to the biofilm cultured ones6. Therefore, increasing the maximum 
growth rate in the sensitivity analysis has led to a faster kill by different antibiotics due to 
the greater exposure of the bacteria to the antibiotic compared to the slowly growing biofilm 
infection. 
Interestingly enough, estimates of the parameter K was higher for antibiotics that are 
concentration dependent (Ciprofloxacin, Rifampin, and Streptomycin) compared to those 
that are time dependent (Ampicillin and Tetracycline) which means that the formers are 
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characterized by a steeper pharmacodynamic function. The steeper the function, the more 
dramatically the bacterial killing is sensitive to the change in antibiotic concentration 
above the MIC. Therefore, it could be a reasonable assumption that for antibiotics that 
have grater K, increasing the concentration above MIC (AUC/MIC) is the most effective 
strategy to improve the treatment outcomes. This hypothesis was fully augmented by the 
PK/PD simulation shown in both Figures 11a and b. Increasing the % t>MIC for Rifampin 
by reducing the dosing interval to 4 hours and even 2 hours did not achieve the target 
outcome for the resistant strain as did the increase in the AUC/MIC. Furthermore, 
Ciprofloxacin achieved the target therapeutic outcome only when the dose increased 
allowing AUC>MIC to increase. It is worth mentioning that the magnitude of the dose 
increase for concentration dependent antibiotics appears to be related to the PD parameter 
K (the Hill coefficient); since Rifampin- has a K value of 2.5 compared to 1.1 for 
Ciprofloxacin- has achieved the target therapeutic outcome upon 1.5 fold increase in the 
dose compared to a four folds increase for Ciprofloxacin. In another way, one can 
conclude that as K increases, as the antibiotic efficacy is more sensitive to small changes in 
concentration. 
On the other hand, it was assumed that lower values of K could be associated with time 
dependence of the antibiotics. This assumption is not fully supported by the current 
simulation, since for Tetracycline (k=0.61) both scenarios of increasing the AUC/MIC and 
% t>MIC worked well and achieved comparable therapeutic outcomes. It is worth 
mentioning, however, that the maintenance dose used in the former scenario (12.08 µg 
every 8 hours) was four times higher than that used in the later scenario (2.95 µg every 2 
hours). Although it is known that longer dosing intervals are more convenient and can 
improve patient adherence to therapy, drug toxicity is an important consideration as well. 
In case where toxicity is expected from higher doses of a time-dependent antibiotic, the 
strategy of dividing the doses into smaller fractions for shorter dosing intervals may be 
considered.  
Finally, it should be noted that this model may suffer some limitations due to many causes. 
The model assumes that the kill rate increases with increasing antibiotic concentration, 
however in reality, the development of an adaptive resistance- a mechanism by which the 
bacteria becomes increasingly refractory to the antibiotic treatment- may lead to the 
decrease in kill rate with time and therefore limit such assumptions. Moreover, the 
constitutive and inducible immune defense of the human body contributes to the efficacy of 
the antibiotic treatment protocols in a way that could not be fully represented by the current 
PK/PD analysis under in vitro conditions.  
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